{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:58:22Z","timestamp":1789095502167,"version":"build-2803163510"},"reference-count":36,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple endocrine neoplasia type 1 (MEN1)-related neuroendocrine tumors (NETs) of the lung are mostly indolent, with a good prognosis. Nevertheless, cases of aggressive lung NET do occur, and therefore the management of individual patients is challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess tumor growth and the survival of patients with MEN1-related lung NETs at long-term follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The population-based Dutch MEN1 Study Group database (n\u2005=\u2005446) was used to identify lung NETs by histopathological and radiological examinations. Tumor diameter was assessed. Linear mixed models and the Kaplan-Meier method were used for analyzing tumor growth and survival. Molecular analyses were performed on a lung NET showing particularly aggressive behavior.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 102 patients (22.9% of the total MEN1 cohort), 164 lesions suspected of lung NETs were identified and followed for a median of 6.6 years. Tumor diameter increased 6.0% per year. The overall 15-year survival rate was 78.0% (95% confidence interval: 64.6\u201394.2%) without lung NET-related death. No prognostic factors for tumor growth or survival could be identified. A somatic c.3127A\u2005&amp;gt;\u2005G (p.Met1043Val) PIK3CA driver mutation was found in a case of rapid growing lung NET after 6 years of indolent disease, presumably explaining the sudden change in course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MEN1-related lung NETs are slow growing and have a good prognosis. No accurate risk factors for tumor growth could be identified. Lung NET screening should therefore be based on well-informed, shared decision-making, balancing between the low absolute risk of an aggressive tumor in individuals and the potential harms of frequent thoracic imaging.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa800","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T06:41:13Z","timestamp":1604299273000},"page":"e1014-e1027","source":"Crossref","is-referenced-by-count":27,"title":["The Management of Neuroendocrine Tumors of the Lung in MEN1: Results From the Dutch MEN1 Study Group"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4656-2960","authenticated-orcid":false,"given":"Medard F M","family":"van den Broek","sequence":"first","affiliation":[{"name":"Department of Endocrine Oncology, University Medical Center Utrecht, GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M","family":"de Laat","sequence":"additional","affiliation":[{"name":"Department of Endocrine Oncology, University Medical Center Utrecht, GA Utrecht, The Netherlands"},{"name":"Department of Internal Medicine, University Medical Center Utrecht, GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel S","family":"van Leeuwaarde","sequence":"additional","affiliation":[{"name":"Department of Endocrine Oncology, University Medical Center Utrecht, GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annenienke C","family":"van de Ven","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Radboud University Medical Center, HB Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W","family":"de Herder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center, CA Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-7580","authenticated-orcid":false,"given":"Olaf M","family":"Dekkers","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Leiden University Medical Center, RC Leiden, The Netherlands"},{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine L","family":"Drent","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Endocrinology, Amsterdam UMC, location VU University Medical Center, MB Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel N","family":"Kerstens","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Medical Center Groningen, University of Groningen, RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H","family":"Bisschop","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Amsterdam UMC, location Academic Medical Center, DD Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Havekes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Maastricht University Medical Center, AZ Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzel M","family":"Hackeng","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht, GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewijk A A","family":"Brosens","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht, GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno R","family":"Vriens","sequence":"additional","affiliation":[{"name":"Department of Endocrine Surgical Oncology, University Medical Center Utrecht, GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wieneke A","family":"Buikhuisen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The Netherlands Cancer Institute, BE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlof D","family":"Valk","sequence":"additional","affiliation":[{"name":"Department of Endocrine Oncology, University Medical Center Utrecht, GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"issue":"5311","key":"2021122205330090900_CIT0001","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science (80)."},{"issue":"1","key":"2021122205330090900_CIT0002","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10689-010-9398-6","article-title":"Care for patients with multiple endocrine neoplasia type 1: the current evidence base","volume":"10","author":"Pieterman","year":"2011","journal-title":"Fam Cancer."},{"key":"2021122205330090900_CIT0003","doi-asserted-by":"crossref","first-page":"705036","DOI":"10.1155\/2012\/705036","article-title":"Genetic and clinical features of multiple endocrine neoplasia types 1 and 2","volume":"2012","author":"Romei","year":"2012","journal-title":"J Oncol."},{"issue":"6","key":"2021122205330090900_CIT0004","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMc1406028","article-title":"Breast-cancer predisposition in multiple endocrine neoplasia type 1","volume":"371","author":"Dreijerink","year":"2014","journal-title":"N Engl J Med."},{"issue":"10","key":"2021122205330090900_CIT0005","doi-asserted-by":"crossref","first-page":"T179","DOI":"10.1530\/ERC-17-0225","article-title":"The future: medical advances in MEN1 therapeutic approaches and management strategies","volume":"24","author":"van Leeuwaarde","year":"2017","journal-title":"Endocr Relat Cancer."},{"issue":"3","key":"2021122205330090900_CIT0006","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/cncr.20825","article-title":"Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1","volume":"103","author":"Sachithanandan","year":"2005","journal-title":"Cancer."},{"issue":"9","key":"2021122205330090900_CIT0007","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1210\/jc.2014-1560","article-title":"Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients","volume":"99","author":"de Laat","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122205330090900_CIT0008","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12672-015-0228-z","article-title":"Thymic and bronchial carcinoid tumors in multiple endocrine Neoplasia Type 1: the mayo clinic experience from 1977 to 2013","volume":"6","author":"Singh Ospina","year":"2015","journal-title":"Horm Cancer."},{"issue":"3","key":"2021122205330090900_CIT0009","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000435921","article-title":"Bronchopulmonary neuroendocrine neoplasms and their precursor lesions in multiple endocrine neoplasia type 1","volume":"103","author":"Bartsch","year":"2016","journal-title":"Neuroendocrinology."},{"issue":"1","key":"2021122205330090900_CIT0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00268-017-4135-z","article-title":"Histologically proven bronchial neuroendocrine tumors in MEN1: a GTE 51-case cohort study","volume":"42","author":"Lecomte","year":"2018","journal-title":"World J Surg."},{"issue":"9","key":"2021122205330090900_CIT0011","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122205330090900_CIT0012","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cen.12972","article-title":"When and how should patients with multiple endocrine neoplasia type 1 be screened for thymic and bronchial carcinoid tumours?","volume":"84","author":"Singh Ospina","year":"2016","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"11","key":"2021122205330090900_CIT0013","doi-asserted-by":"crossref","first-page":"R260","DOI":"10.1530\/EC-18-0359","article-title":"\u201cQuality in, quality out,\u201d a stepwise approach to evidence-based medicine for rare diseases promoted by multiple endocrine neoplasia type 1","volume":"7","author":"van Beek","year":"2018","journal-title":"Endocr Connect."},{"issue":"6","key":"2021122205330090900_CIT0014","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1067\/msy.2000.109727","article-title":"Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?","volume":"128","author":"Bartsch","year":"2000","journal-title":"Surgery."},{"issue":"10","key":"2021122205330090900_CIT0015","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/hmg\/ddt039","article-title":"Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d\u2019etude des Tumeurs Endocrines (GTE) cohort study","volume":"22","author":"Thevenon","year":"2013","journal-title":"Hum Mol Genet."},{"issue":"11","key":"2021122205330090900_CIT0016","doi-asserted-by":"crossref","first-page":"E2387","DOI":"10.1210\/jc.2013-4432","article-title":"Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain","volume":"99","author":"Bartsch","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021122205330090900_CIT0017","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1210\/jc.2017-00372","article-title":"Long-term natural course of small nonfunctional pancreatic neuroendocrine tumors in MEN1-results from the Dutch MEN1 Study Group","volume":"102","author":"Pieterman","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122205330090900_CIT0018","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol."},{"key":"2021122205330090900_CIT0019","first-page":"73","article-title":"Carcinoid tumor","volume-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart.","author":"Beasley","year":"2015","edition":"4th ed."},{"issue":"10","key":"2021122205330090900_CIT0020","doi-asserted-by":"crossref","first-page":"T243","DOI":"10.1530\/ERC-17-0285","article-title":"The future: surgical advances in MEN1 therapeutic approaches and management strategies","volume":"24","author":"Sadowski","year":"2017","journal-title":"Endocr Relat Cancer."},{"key":"2021122205330090900_CIT0021","article-title":"Supplementary material of \u201cthe management of neuroendocrine tumors of the lung in MEN1: results from the Dutch MEN1 Study Group.\u201d","author":"van den Broek","year":"2020","journal-title":"Dataverse NL Repos"},{"key":"2021122205330090900_CIT0022","author":"Hartwig Medical Foundation."},{"key":"2021122205330090900_CIT0023","article-title":"Conumee: enhanced copy-number variation analysis using Illumina DNA methylation arrays","volume-title":"R package version 1.9.0","author":"Hovestadt"},{"key":"2021122205330090900_CIT0024","author":"Hartwig Medical Foundation."},{"issue":"2","key":"2021122205330090900_CIT0025","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12022-020-09611-8","article-title":"Alternative lengthening of telomeres and differential expression of endocrine transcription factors distinguish metastatic and non-metastatic insulinomas","volume":"31","author":"Hackeng","year":"2020","journal-title":"Endocr Pathol."},{"issue":"5","key":"2021122205330090900_CIT0026","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/cen.13573","article-title":"An assessment of 18 F-FDG PET\/CT for thoracic screening and risk stratification of pulmonary nodules in multiple endocrine neoplasia type 1","volume":"88","author":"So","year":"2018","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"2021122205330090900_CIT0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-016-0708-1","article-title":"MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients","volume":"14","author":"de Laat","year":"2016","journal-title":"BMC Med."},{"key":"2021122205330090900_CIT0028","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semcancer.2019.02.002","article-title":"PIK3CA in cancer: The past 30 years","volume":"59","author":"Arafeh","year":"2019","journal-title":"Semin Cancer Biol."},{"issue":"75","key":"2021122205330090900_CIT0029","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med."},{"issue":"3","key":"2021122205330090900_CIT0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/thx.2006.063065","article-title":"Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease","volume":"62","author":"Davies","year":"2007","journal-title":"Thorax."},{"key":"2021122205330090900_CIT0031","doi-asserted-by":"crossref","first-page":"975","DOI":"10.12659\/AJCR.904468","article-title":"Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a case report and review of the literature","volume":"18","author":"Koliakos","year":"2017","journal-title":"Am J Case Rep."},{"issue":"9","key":"2021122205330090900_CIT0032","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s12149-012-0634-z","article-title":"Impact of Ga-68 DOTATOC PET\/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia","volume":"26","author":"Froeling","year":"2012","journal-title":"Ann Nucl Med."},{"issue":"2","key":"2021122205330090900_CIT0033","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jamcollsurg.2015.04.005","article-title":"Results of (68)Gallium-DOTATATE PET\/CT scanning in patients with multiple endocrine Neoplasia Type 1","volume":"221","author":"Sadowski","year":"2015","journal-title":"J Am Coll Surg."},{"issue":"3","key":"2021122205330090900_CIT0034","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s12020-015-0702-y","article-title":"Role of (68)Ga-DOTATATE PET\/CT in patients with multiple endocrine neoplasia type 1 (MEN1)","volume":"52","author":"Lastoria","year":"2016","journal-title":"Endocrine."},{"issue":"6","key":"2021122205330090900_CIT0035","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00268-017-3907-9","article-title":"Limited value of Ga-68-DOTATOC-PET-CT in routine screening of patients with multiple endocrine Neoplasia Type 1","volume":"41","author":"Albers","year":"2017","journal-title":"World J Surg."},{"key":"2021122205330090900_CIT0036","article-title":"Understanding the clinical course of genotype-negative MEN1 patients can inform management strategies","author":"Pieterman","year":"2020.","journal-title":"Surg (United States)."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa800\/34880806\/dgaa800.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/2\/e1014\/41849639\/dgaa800.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/2\/e1014\/41849639\/dgaa800.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:36:52Z","timestamp":1640133412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/2\/e1014\/5950352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2021,1,23]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa800","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,11,2]]}}}